Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business6 October 2016Corporate and M&ADeal watch Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryHSBC’s Stephanie Hamon on how AI is becoming a must for panel firmsRevolving Doors: City hires at Goodwin, Ropes as Willkie brings in former CC antitrust head‘Growth is the magic word’ – how the UK’s competition watchdog is shaping the deal landscapeFreshfields takes headline role on £575m Telegraph acquisitionDLA Piper and Proskauer lead on BrewDog’s sale to US cannabis and drinks manufacturerPaul Hastings hires London M&A partner from Slaughter and MayDealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealDealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanDeal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture